The Future of LAAC-In 5, 10, and 20 Years

Matthew J Daniels; Adrian Parry-Jones

doi:10.1016/j.iccl.2021.11.011

The Future of LAAC-In 5, 10, and 20 Years

Matthew J Daniels, Adrian Parry-Jones

Division of Cardiovascular Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Early experience with percutaneous LAA closure documented complication rates of ∼10%, with failure to implant devices in ∼10% of patients. These numbers are unrecognizable in contemporary practice due to the iterative changes made largely in the last 10 years. Here we look forward to ask what might change, and when, to bring percutaneous LAA closure out of the niche early adopter centers into routine use. We consider the opportunity to incorporate different technologies into LAAc devices in the context of managing patient with atrial fibrillation. Finally, we consider how to make the procedure safer and more effective.

Original language	English
Pages (from-to)	219-231
Number of pages	13
Journal	Interventional Cardiology Clinics
Volume	11
Issue number	2
Early online date	10 Mar 2022
DOIs	https://doi.org/10.1016/j.iccl.2021.11.011
Publication status	Published - 1 Apr 2022

Keywords

Atrial fibrillation
Device thrombus
Intracerebral hemorrhage
Invasive pressure monitor
Left atrial appendage
Oral anticoagulant

Access to Document

10.1016/j.iccl.2021.11.011

Cite this

@article{c992bbcd4bc24b1b843c99f2aabf1a15,

title = "The Future of LAAC-In 5, 10, and 20 Years",

abstract = "Early experience with percutaneous LAA closure documented complication rates of ∼10%, with failure to implant devices in ∼10% of patients. These numbers are unrecognizable in contemporary practice due to the iterative changes made largely in the last 10 years. Here we look forward to ask what might change, and when, to bring percutaneous LAA closure out of the niche early adopter centers into routine use. We consider the opportunity to incorporate different technologies into LAAc devices in the context of managing patient with atrial fibrillation. Finally, we consider how to make the procedure safer and more effective.",

keywords = "Atrial fibrillation, Device thrombus, Intracerebral hemorrhage, Invasive pressure monitor, Left atrial appendage, Oral anticoagulant",

author = "Daniels, {Matthew J} and Adrian Parry-Jones",

note = "Funding Information: Conflicts: M.J. Daniels research grant & speaker honorarium Abbott, Consultant ? WL GORE & Associates, Advisory Board fees Bristol Myers Squibb; A. Parry-Jones Speaker and Advisory Board fees from Alexion Pharmaceuticals.",

year = "2022",

month = apr,

day = "1",

doi = "10.1016/j.iccl.2021.11.011",

language = "English",

volume = "11",

pages = "219--231",

journal = "Interventional Cardiology Clinics",

issn = "2211-7458",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - The Future of LAAC-In 5, 10, and 20 Years

AU - Daniels, Matthew J

AU - Parry-Jones, Adrian

N1 - Funding Information: Conflicts: M.J. Daniels research grant & speaker honorarium Abbott, Consultant ? WL GORE & Associates, Advisory Board fees Bristol Myers Squibb; A. Parry-Jones Speaker and Advisory Board fees from Alexion Pharmaceuticals.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - Early experience with percutaneous LAA closure documented complication rates of ∼10%, with failure to implant devices in ∼10% of patients. These numbers are unrecognizable in contemporary practice due to the iterative changes made largely in the last 10 years. Here we look forward to ask what might change, and when, to bring percutaneous LAA closure out of the niche early adopter centers into routine use. We consider the opportunity to incorporate different technologies into LAAc devices in the context of managing patient with atrial fibrillation. Finally, we consider how to make the procedure safer and more effective.

AB - Early experience with percutaneous LAA closure documented complication rates of ∼10%, with failure to implant devices in ∼10% of patients. These numbers are unrecognizable in contemporary practice due to the iterative changes made largely in the last 10 years. Here we look forward to ask what might change, and when, to bring percutaneous LAA closure out of the niche early adopter centers into routine use. We consider the opportunity to incorporate different technologies into LAAc devices in the context of managing patient with atrial fibrillation. Finally, we consider how to make the procedure safer and more effective.

KW - Atrial fibrillation

KW - Device thrombus

KW - Intracerebral hemorrhage

KW - Invasive pressure monitor

KW - Left atrial appendage

KW - Oral anticoagulant

U2 - 10.1016/j.iccl.2021.11.011

DO - 10.1016/j.iccl.2021.11.011

M3 - Article

C2 - 35361466

AN - SCOPUS:85126318522

SN - 2211-7458

VL - 11

SP - 219

EP - 231

JO - Interventional Cardiology Clinics

JF - Interventional Cardiology Clinics

IS - 2

ER -

The Future of LAAC-In 5, 10, and 20 Years

Abstract

Keywords

Access to Document

Fingerprint

Cite this